Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4 ‐ IgG + NMOSD Treated With Rituximab—A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group ( NEMOS )
European Journal of Neurology · 2026
DOI: 10.1111/ene.70520 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Daniel Engels und 29 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Neuroimmunology and Biomedical Center (BMC), LMU University Hospital, Faculty of Medicine, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Rituximab, Neuromyelitis Optica, Immunoglobulin G, Aquaporin 4. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Rituximab is effective and widely used as long‐term treatment in aquaporin‐4‐IgG‐positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD). However, infections remain a significant concern during rituximab treatment.
Methods
We conducted a retrospective multicenter cohort study within the NMO Study Group (NEMOS) in Germany, analyzing demographic and clinical data from people with AQP4‐IgG+ NMOSD receiving rituximab or azathioprine by retrospective chart, and compared infection occurrence and severity. For rituximab‐treated patients, we collected laboratory data (blood lymphocytes, B‐cell counts, serum IgG, IgM, and IgA levels), assessed risk factors for infections, and determined the probability of infection within a 3‐month window before and after the laboratory assessment.
Results
In 92/170 rituximab and in 12/33 azathioprine treatment episodes, one or more infections were documented. Rituximab and azathioprine showed comparable types and risk of infection (HR = 1.24, 95% CI: 0.68–2.25). Rituximab‐treated individuals older than 60 years had a higher risk of infection (HR = 1.62, 95% CI: 1.02–2.57). Hypogammaglobulinemia (IgG < 6.0 g/L: OR = 2.27, 95% CI: 1.15–4.48; IgM < 0.3 g/L: OR = 2.08, 95% CI: 1.05–4.09) predicted infections and the occurrence of both low IgG and IgM serum levels further increased the risk of infection (OR = 2.77, 95% CI: 1.10–6.98) during rituximab treatment. Low IgG and IgA serum levels as well as lymphopenia predicted infection‐related hospitalizations.
Conclusion
Age > 60 years and immunoglobulin serum levels during rituximab treatment may serve as predictors for infection and help to individualize treatment decisions in NMOSD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Neuroimmunology and Biomedical Center (BMC), LMU University Hospital, Faculty of Medicine, LMU Munich, Munich, Germany.
- Department of Neurology, University of Leipzig, Leipzig, Germany.
- Department of Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Department of Neurology, St. Josef Hospital, Ruhr University, Bochum, Germany.
- Department of Neurology, Centre for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University, Düsseldorf, Germany.
- Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University, Düsseldorf, Germany.
ORCID-Profile: Daniel Engels, Charlotte Schubert, Insa Schiffmann, Ioannis Vardakas, Clemens Warnke, Tania Kümpfel
Zitieren
APA
Engels, D., Herfurth, M., Havla, J., Schindler, P., Ruprecht, K., Schwake, C., Ringelstein, M., Fischer, K., Schubert, C., Schiffmann, I., Hümmert, M. W., Giglhuber, K., Jarius, S., Vardakas, I., Grothe, M., Etgen, T., Warnke, C., Naumann, J., Hoffmann, F., …, & Neuromyelitis Optica Study Group (NEMOS) (2026). Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4 ‐ IgG + NMOSD Treated With Rituximab—A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group ( NEMOS ). European Journal of Neurology. https://doi.org/10.1111/ene.70520
Vancouver
Engels D, Herfurth M, Havla J, Schindler P, Ruprecht K, Schwake C, et al. Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4 ‐ IgG + NMOSD Treated With Rituximab—A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group ( NEMOS ). European Journal of Neurology. 2026. doi:10.1111/ene.70520
BibTeX
@article{Engels2026,
author = {Engels, Daniel and Herfurth, Mariella and Havla, Joachim and Schindler, Patrick and Ruprecht, Klemens and Schwake, Carolin and Ringelstein, Marius and Fischer, Katinka and Schubert, Charlotte and Schiffmann, Insa and Hümmert, Martin W and Giglhuber, Katrin and Jarius, Sven and Vardakas, Ioannis and Grothe, Matthias and Etgen, Thorleif and Warnke, Clemens and Naumann, Jasmin and Hoffmann, Frank and Senel, Makbule and Wildemann, Brigitte and Berthele, Achim and Trebst, Corinna and Häußler, Vivien and Aktas, Orhan and Ayzenberg, Ilya and Bellmann-Strobl, Judith and Bergh, Florian Then and Kümpfel, Tania and Neuromyelitis Optica Study Group (NEMOS), Neuromyelitis Optica Study Group (NEMOS)},
title = {Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4 ‐ IgG + NMOSD Treated With Rituximab—A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group ( NEMOS )},
journal = {European Journal of Neurology},
year = {2026},
doi = {10.1111/ene.70520}
}
EUVIMED